These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 1350486)

  • 41. Blood pressure lowering efficacy of dual alpha and beta blockers for primary hypertension.
    Wong GW; Laugerotte A; Wright JM
    Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD007449. PubMed ID: 26306578
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.
    McTavish D; Campoli-Richards D; Sorkin EM
    Drugs; 1993 Feb; 45(2):232-58. PubMed ID: 7681374
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The effects of intravenous carvedilol, a new multiple action vasodilatory beta-blocker, in congestive heart failure.
    DasGupta P; Broadhurst P; Lahiri A
    J Cardiovasc Pharmacol; 1991; 18 Suppl 4():S12-6. PubMed ID: 1721973
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Influence of salt intake on the antihypertensive effect of carvedilol.
    Ruilope LM; Lahera V
    J Hypertens Suppl; 1993 Jun; 11(4):S17-9. PubMed ID: 8104238
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Vasodilating beta-blockers in heart failure.
    Raftery EB
    Eur Heart J; 1995 Jul; 16 Suppl F():32-7. PubMed ID: 8521882
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A new molecule with vasodilating and beta-adrenoceptor blocking properties.
    Abshagen U
    J Cardiovasc Pharmacol; 1987; 10 Suppl 11():S23-32. PubMed ID: 2454364
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The vasodilatory beta-blockers.
    Pedersen ME; Cockcroft JR
    Curr Hypertens Rep; 2007 Aug; 9(4):269-77. PubMed ID: 17686376
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Protective effects of carvedilol, a vasodilating beta-adrenoceptor blocker, against in vivo low density lipoprotein oxidation in essential hypertension.
    Maggi E; Marchesi E; Covini D; Negro C; Perani G; Bellomo G
    J Cardiovasc Pharmacol; 1996 Apr; 27(4):532-8. PubMed ID: 8847870
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Experimental and clinical pharmacology of carvedilol and other drugs combining vasodilation and beta-adrenoceptor antagonism in a single molecule.
    Strein K; Sponer G
    Z Kardiol; 1990; 79 Suppl 3():89-98. PubMed ID: 1983054
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Resting and postexercise hemodynamic effects of carvedilol, a beta-adrenergic blocker and precapillary vasodilator in hypertensive patients.
    Leonetti G; Sampieri L; Cuspidi C; Boselli L; Terzoli L; Rupoli L; Zanchetti A
    J Cardiovasc Pharmacol; 1987; 10 Suppl 11():S94-6. PubMed ID: 2454377
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Acute and long-term hemodynamic effects of carvedilol, a combined beta-adrenoceptor blocking and precapillary vasodilating agent, in hypertensive patients.
    Eggertsen R; Sivertsson R; Andrén L; Hansson L
    J Cardiovasc Pharmacol; 1987; 10 Suppl 11():S97-100. PubMed ID: 2454378
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Vasodilatory action of carvedilol.
    Sponer G; Strein K; Bartsch W; Müller-Beckmann B
    J Cardiovasc Pharmacol; 1992; 19 Suppl 1():S5-11. PubMed ID: 1378150
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of long-term carvedilol therapy on renal function in essential hypertension.
    Tomita K; Marumo F
    J Cardiovasc Pharmacol; 1992; 19 Suppl 1():S97-101. PubMed ID: 1378158
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Differential effects of beta-blockers in patients with heart failure: A prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol.
    Metra M; Giubbini R; Nodari S; Boldi E; Modena MG; Dei Cas L
    Circulation; 2000 Aug; 102(5):546-51. PubMed ID: 10920067
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of carvedilol on left ventricular function and mass in hypertension.
    Why HJ; Richardson PJ
    J Cardiovasc Pharmacol; 1992; 19 Suppl 1():S50-4. PubMed ID: 1378151
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Echo-Doppler mitral flow monitoring: an operative tool to evaluate day-to-day tolerance to and effectiveness of beta-adrenergic blocking agent therapy in patients with chronic heart failure.
    Capomolla S; Pinna GD; Febo O; Caporotondi A; Guazzotti G; La Rovere MT; Gnemmi M; Mortara A; Maestri R; Cobelli F
    J Am Coll Cardiol; 2001 Nov; 38(6):1675-84. PubMed ID: 11704380
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Carvedilol.
    Crysant SG
    Arch Fam Med; 1999; 8(4):295. PubMed ID: 10418532
    [No Abstract]   [Full Text] [Related]  

  • 58. Carvedilol, a novel vasodilating beta-blocker with the potential for cardiovascular organ protection.
    Feuerstein GZ; Ruffolo RR
    Eur Heart J; 1996 Apr; 17 Suppl B():24-9. PubMed ID: 8733068
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical efficacy of carvedilol in severe hypertension.
    Ogihara T; Yoshinaga K; Kamahara Y; Ikeda M; Goto Y; Arakawa K; Iimura I; Ishii M; Kokubu T; Takeda T
    J Cardiovasc Pharmacol; 1991; 18 Suppl 4():S69-72. PubMed ID: 1721983
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Can intravenous beta blockade predict long-term haemodynamic benefit in chronic congestive heart failure secondary to ischaemic heart disease? A comparison between intravenous and oral carvedilol.
    DasGupta P; Lahiri A
    Clin Investig; 1992; 70 Suppl 1():S98-104. PubMed ID: 1350492
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.